Ovarian hyperstimulation syndrome and complications of ART

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 23, Issue 5, 2009, Pages 691-709

  Vloeberghs, Veerle ^a   Peeraer, Karen ^a   Pexsters, Anne ^a   D'Hooghe, Thomas ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

ART; complications; oocyte retrieval; ovarian hyperstimulation syndrome; ovarian stimulation

Indexed keywords

ALBUMIN; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIEMETIC AGENT; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; FOLLITROPIN RECEPTOR; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; NARCOTIC ANALGESIC AGENT; PARACETAMOL; RECOMBINANT LUTEINIZING HORMONE; VASCULOTROPIN; ELECTROLYTE; VASCULOTROPIN A;

ABDOMINAL BLEEDING; ADNEXA DISEASE; ANOVULATION; ARTERY DILATATION; ARTICLE; ASCITES; CLINICAL FEATURE; CLINICAL TRIAL; CRYOPRESERVATION; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FERTILIZATION IN VITRO; FLUID THERAPY; FOLLICULAR ASPIRATION; GENE MUTATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFERTILITY; INFERTILITY THERAPY; INTENSIVE CARE; LAPAROSCOPIC SURGERY; NAUSEA; OOCYTE MATURATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARIAN BLEEDING; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATHOPHYSIOLOGY; PATIENT COUNSELING; PELVIC INFLAMMATORY DISEASE; PREGNANCY RATE; PRIMARY PREVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; SINGLE DRUG DOSE; SURGICAL DRAINAGE; TREATMENT DURATION; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; VOMITING; ADNEXAL DISEASES; AMBULATORY CARE; BLEEDING; FEMALE; GENETICS; MUTATION; OVARIAN HYPERSTIMULATION SYNDROME; PHYSIOLOGY; PROCEDURES; THROMBOEMBOLISM; TORSION ABNORMALITY; VASODILATATION;

ADNEXAL DISEASES; AMBULATORY CARE; ANTICOAGULANTS; CRYOPRESERVATION; ELECTROLYTES; FEMALE; FLUID THERAPY; HEMORRHAGE; HOSPITALIZATION; HUMANS; INTENSIVE CARE; MUTATION; OOCYTE RETRIEVAL; OVARIAN HYPERSTIMULATION SYNDROME; PELVIC INFLAMMATORY DISEASE; RECEPTORS, FSH; RENIN-ANGIOTENSIN SYSTEM; REPRODUCTIVE TECHNIQUES, ASSISTED; RISK FACTORS; THROMBOEMBOLISM; TORSION ABNORMALITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATION;

EID: 69449104248     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2009.02.006     Document Type: Article

References (119)

1. Boivin J., Bunting L., Collins J.A., et al. New debate: international estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 22 (2007) 1506-1512
2. De Sutter P., Gerris J., and Dhont M. Assisted reproductive technologies: how to minimise the risks and complications in developing countries?. Hum Reprod (2008) 73-76
3. Delvigne A., and Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 9 1 (2003) 77-96
4. Delbaere A., Bergmann P.J.M., Gervy-Decoster C., et al. Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Fertil Steril 67 6 (1997) 1038-1045
5. Delvigne A., and Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 8 6 (2002) 559-577
6. Navot D., Bergh P.A., and Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58 2 (1992) 249-261
7. Golan A., Ron-El R., Herman A., et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 44 6 (1989) 430-440
8. Brinsden P.R., Wada I., Tan S.L., et al. Review: diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 102 (1995) 767-772
9. Serour G.I., Aboulghar M., Mansour R., et al. Complications of medically assisted conception in 3,500 cycles. Fertil Steril 70 4 (1998) 638-642
10. Braat D., Bernardus R., and Gerris J. Anonymous reports of lethal cases of ovarian hyperstimulation syndrome. In: Gerris J., Olivennes F., and Delvigne A. (Eds). Ovarian hyperstimulation syndrome (2006), Informa Healthcare, UK 59-70
11. Aboulghar M.A., and Mansour R.T. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 9 3 (2003) 275-289
12. Rizk B., and Aboulghar M.A. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: Brinsden P. (Ed). In vitro fertilization and assisted reproduction (1999), The Parthenon Publishing Group, New York, London 131-155
13. Royal College of Obstetricians and Gynaecologists (RCOG). The management of ovarian hyperstimulation syndrome. Green-top Guideline 5 (2006) 1-11
14. Mathur R.S., Akande A.V., Keay S.D., et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 73 5 (2000) 901-907
15. Papanikolaou E.G., Tournaye H., Verpoest W., et al. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod Update 20 3 (2005) 636-641
16. European Society of Human Reproduction (ESHRE). Special Interest Group (SIG) guidelines on ovarian hyperstimulation syndrome (OHSS). Available from: (2005). http://www.eshre.com/emc
17. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril 86 4 (2006) S178-S183
18. Gorkemli H., Camus M., and Clasen K. Adnexal torsion after gonadotrophin ovulation induction for IVF of ICSI and its conservative treatment. Arch Gynecol Obstet 267 (2002) 4-6
19. Källén B. Maternal morbidity and mortality in in-vitro fertilization. Best Pract Res Clin Obstet Gynaecol 22 3 (2008) 549-558
20. Mashiach S., Bider D., Moran O., et al. Adnexal torsion of hyperstimulated ovaries in pregnancies after gonadotropin therapy. Fertil Steril 53 1 (1990) 76-80
21. Fleischer A.C., and Brader K.R. Sonographic depiction of ovarian vascularity and flow: current improvements and future applications. J Ultrasound Med 20 3 (2001) 241-250
22. Oelsner G., Cohen S.B., Soriano D., et al. Minimal surgery for the twisted ischaemic adnexa can preserve ovarian function. Hum Reprod 18 12 (2003) 2599-2602
23. Roest J., Mous H.V.H., Zeilmaker G.H., et al. The incidence of major clinical complications in a Dutch transport IVF programme. Hum Reprod Update 2 4 (1996) 345-353
24. Maxwell KN, Cholst IN, Rosenwaks Z. The incidence of both serious and minor complications in young women undergoing oocyte donation. Fertil Steril 2008; 90(6): 2165-2171.
25. Govaerts I., Devreker F., Delbaere A., et al. Short-term medical complications of 1500 oocyte retrievals for in vitro fertilization and embryo transfer. Eur J Obstet Gynecol Reprod Biol 77 (1998) 239-243
26. Bodri D., Guillén J.J., Polo A., et al. Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles. Reprod Biomed Online 17 2 (2008) 237-243
27. Chan W.S., and Dixon M.E. Review article: the "ART" of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res 121 (2008) 713-726
28. Stewart J.A., Hamilton P.J., and Murdoch A.P. Opinion: thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 12 10 (1997) 2167-2173
29. Chan W.S., and Ginsberg J.S. Review article: a review of upper extremity deep vein thrombosis in pregnancy: unmasking the 'ART' behind the clot. J Thromb Haemost 4 (2006) 1673-1677
30. Mára M., Koryntová D., Rezábek K., et al. Thromboembolic complications in patients undergoing in vitro fertilization: retrospective clinical study. Ceska Gynekol 69 4 (2004) 312-316
31. Kodama H., Fukuda J., Karube H., et al. Characteristics of blood hemostatic markers in a patient with ovarian hyperstimulation syndrome who actually developed thromboembolism. Fertil Steril 64 6 (1995) 1207-1209
32. Kodama H., Fukuda J., Karube H., et al. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil Steril 66 3 (1996) 417-424
33. Balasch J., Reverter J.C., Fábregues F., et al. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil Steril 66 4 (1996) 608-613
34. Baumann P., and Diedrich K. Thromboembolic complications associated with reproductive endocrinologic procedures. Hematol Oncol Clin North Am 14 2 (2000) 431-443
35. Arya A., Shehata H.A., Patel Raj K., et al. Short report: internal jugular vein thrombosis after assisted conception therapy. Br J Haematol 115 (2001) 153-155
36. Dulitzky M., Cohen S.B., Inbal A., et al. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril 77 3 (2002) 463-467
37. Seligsohn U., and Lubetsky A. Medical progress. Genetic susceptibility to venous thrombosis. N Engl J Med 344 16 (2001) 1222-1231
38. Balasch J., Fábregues F., and Arroyo V. Peripheral arterial vasodilation hypothesis: a new insight into the pathogenesis of ovarian hyperstimulation syndrome. Hum Reprod 13 10 (1998) 2718-2730
39. Vlahos N.F., and Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci 1092 (2006) 247-264
40. Amarin Z.O. Debate: bilateral partial oophorectomy in the management of severe ovarian hyperstimulation syndrome. Hum Reprod Update 18 4 (2003) 659-664
41. Villasante A., Pacheco A., Ruiz A., et al. Vascular endothelial cadherin regulates vascular permeability: implications for ovarian hyperstimulation syndrome. J Clin Endocr Metab 92 1 (2007) 314-321
42. Soares S.R., Gómez R., Simón C., et al. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 14 4 (2008) 321-333
43. Gómez R., Simón C., Remohí J., et al. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 143 11 (2002) 4339-4348
44. Neufeld G., Cohen T., Gengrinovitch S., et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1999) 9-22
45. Waltenberger J., Claesson-Welsh L., Siegbahn A., et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269 43 (1994) 26988-26995
46. Kendall R.L., Wang G., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226 (1996) 324-328
47. Gómez R., Simón C., Remohí J., et al. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 68 (2003) 2164-2171
48. Abramov Y., Barak V., Nisman B., et al. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 67 2 (1997) 261-265
49. Robertson D., Selleck K., Suikkari A.M., et al. Research-article: endocrinology and paracrinology: urinary vascular endothelial growth factor concentrations in women undergoing gonadotrophin treatment. Hum Reprod 10 9 (1995) 2478-2482
50. Agrawal R., Tan S.L., Wild S., et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril 71 2 (1999) 287-293
51. Pellicer A., Albert C., Mercader A., et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1β, and interleukin-6, and vascular endothelial growth factor. Fertil Steril 71 3 (1999) 482-489
52. Neulen J., Yan Z., Raczek S., et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocr Metab 80 6 (1995) 1967-1971
53. Neulen J., Raczek S., Pogorzelski M., et al. Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. Mol Hum Reprod 4 3 (1998) 203-206
54. Pau E., Alonso-Muriel I., Gómez R., et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod 21 6 (2006) 1453-1460
55. Gómez R., Lima I., Simón C., et al. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats. Reproduction 127 (2004) 483-489
56. Gómez R., Gonzalez-Izquierdo M., Zimmermann R.C., et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147 11 (2006) 5400-5411
57. Alvarez C., Alonso-Muriel I., García G., et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 22 12 (2007) 3210-3214
58. Balen A.H. Complications of ovarian stimulation. In: Balen A.H. (Ed). Infertility in practice. 3th edn. (2008), Informa Healthcare, UK 359-378
59. Na vot D., Margalioth E.J., Laufer N., et al. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48 1 (1987) 57-61
60. Teruel M.J., and García I.H. Renin-angiotensin system in the pathophysiology of ovarian hyperstimulation syndrome. In: Gerris J., Olivennes F., and Delvigne A. (Eds). Ovarian hyperstimulation syndrome (2006), Informa Healthcare, UK 97-106
61. Teruel M.J., Carbonell L.F., Teruel M.G., et al. Effect of angiotensin-converting enzyme inhibitor on renal function in ovarian hyperstimulation syndrome in the rabbit. Fertil Steril 76 6 (2001) 1232-1237
62. Balasch J., Arroyo V., Fábregues F., et al. Neurohormonal and hemodynamic changes in severe cases of the ovarian hyperstimulation syndrome. Ann Intern Med 121 (1994) 27-33
63. Check J.H., Choe J.K., and Nazari A. Hyperreactio luteinalis despite the absence of a corpus luteum and suppressed serum follicle stimulating concentrations in a triplet pregnancy. Hum Reprod 15 5 (2000) 1043-1045
64. Ludwig M., Gembruch U., Bauer O., et al. Case report: ovarian hyperstimulation syndrome (OHSS) in a spontaneous pregnancy with fetal and placental triploidy: information about the general pathophysiology of OHSS. Hum Reprod 13 8 (1998) 2082-2087
65. Nappi R.G., Di Naro E., D'Aries A.P., et al. Natural pregnancy in hypothyroid woman complicated by spontaneous ovarian hyperstimulation syndrome. Am J Obstet Gynecol (1998) 610-611
66. Delbaere A., Smits G., Olatunbosun O., et al. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?. Hum Reprod 19 3 (2004) 486-489
67. Smits G., Olatunbosun O., Delbaere A., et al. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 349 8 (2003) 760-766
68. Delbaere A., Smits G., De Leener A., et al. Understanding ovarian hyperstimulation syndrome. Endocrine 26 3 (2005) 285-289
69. Al-Inany H.G., Abou-Setta A.M., and Aboulghar M. Review: gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane Review. Reprod Biomed Online 14 5 (2007) 640-649
70. Zhao JZ, Zhou W, Zhang W, et al. Clinical Article: In vitro maturation and fertilization of oocytes from unstimulated ovaries in infertile women with polycystic ovary syndrome. Fertil Steril, in press. doi:10.1016/j.fertnstert.2008.03.059.
71. Delvigne A., and Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid hyperstimulation syndrome in IVF patients. Hum Reprod Update 8 3 (2002) 291-296
72. Asch R.H., Li H.P., Balmaceda J.P., et al. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod 6 10 (1991) 1395-1399
73. Sher G., Zouves C., Feinman M., et al. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization. Hum Reprod 10 12 (1995) 3107-3109
74. Fluker M.R., Hooper W.M., and Yuzpe A.A. Withholding gonadotropins ("coasting") to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. Fertil Steril 71 2 (1999) 294-301
75. García-Velasco J.A., Zúňiga A., Pacheco A., et al. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod 19 7 (2004) 1530-1538
76. Levinsohn-Tavor O., Friedler S., Schachter M., et al. Opinion: coasting-what is the best formula?. Hum Reprod Update 18 5 (2003) 937-940
77. García-Velasco J.A., Isaza V., Quea G., et al. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing?. Fertil Steril 85 3 (2006) 547-554
78. D'Angelo A., and Amso N. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. (Review). Cochrane Database Syst Rev 3 (2002) CD002811
79. Delvigne A., and Rozenberg S. Opinion: preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod 16 12 (2001) 2491-2495
80. Orvieto R. Debate: prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod 18 4 (2003) 665-667
81. Gerris J., De Sutter P., Bosteels J., et al. Ovarieel hyperstimulatiesyndroom (OHSS). VVOG-Standpunt. Available from: (2005). http://www.vvog.be
82. Ulug U., Bahceci M., Erden H.F., et al. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 17 2 (2002) 310-313
83. Moreno L., Pacheco A., Zúňiga A., et al. Extended coasting duration exerts a negative impact on IVF cycle outcome due to premature luteinization. Reprod Biomed Online 9 5 (2004) 500-504
84. Schmidt D.W., Maier D.B., Nulsen J.C., et al. Reducing the dose of human chorionic gonadotropin in high responders does affect the outcomes of in vitro fertilization. Fertil Steril 82 4 (2004) 841-846
85. The European Recombinant LH Study Group. Recombinant human luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocr Metab 86 6 (2001) 2607-2618
86. Griesinger G., Diedrich K., Devroey P., et al. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 12 2 (2006) 159-168
87. Kol S., and Solt I. GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?. J Assist Reprod Genet 25 (2008) 63-66
88. Aboulghar M., Evers J.H., and Al-Inany H. Intravenous albumin for preventing severe ovarian hyperstimulation syndrome: a Cochrane Review. Hum Reprod 17 12 (2002) 3027-3032
89. Bellver J., Muňoz E.A., Ballesteros A., et al. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. Hum Reprod 18 11 (2003) 2283-2288
90. Graf M.A., Fischer R., Naether O.G.J., et al. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme. Hum Reprod 12 12 (1997) 2599-2602
91. Gokmen O., Ugur M., Ekin M., et al. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study. Eur J Obstet Gynecol Reprod Biol 96 (2001) 187-192
92. König E., Bussen S., Sütterlin M., et al. Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study. Hum Reprod 13 9 (1998) 2421-2424
93. D'Angelo A., and Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. (Review). Cochrane Database Syst Rev 3 (2007) CD002806
94. Endo T., Honnma H., Hayashi T., et al. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod 17 10 (2002) 2548-2551
95. Fatemi H.M., Popovic-Todorovic B., Papanikolaou E., et al. An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 13 6 (2007) 581-590
96. Ferraretti A.P., Gianaroli L., Diotallevi L., et al. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 7 2 (1992) 180-183
97. Budev M.M., Arroliga A.C., and Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med 33 10 (2005) S301-S306
98. Wikland M., Enk L., and Hamberger L. Transvesical and transvaginal approaches for the aspiration of follicles by use of ultrasound. Ann N Y Acad Sci 442 (2006) 182-194
99. Bergh T., and Lundkvist O. Short communication: clinical complications during in-vitro fertilization treatment. Hum Reprod 7 5 (1992) 625-626
100. Bennett S.J., Waterstone J.J., Cheng W.C., et al. Complications of transvaginal ultrasound-directed follicle aspiration: a review of 2670 consecutive procedures. J Assist Reprod Genet 10 1 (1993) 72-77
101. Dicker D., Ashkenazi J., Feldberg D., et al. Severe abdominal complications after transvaginal ultrasonographically guided retrieval of oocytes for in vitro fertilization and embryo transfer. Fertil Steril 59 6 (1993) 1313-1315
102. Tureck R.W., García C.R., Blasco L., et al. Perioperative complications arising after transvaginal oocyte retrieval. Obstet Gynecol 81 4 (1993) 590-593
103. Nyboe Andersen A., Gianaroli L., Felberbaum R., et al. Assisted reproductive technology in Europe, 2001. Results generated from European registers by ESHRE. Hum Reprod 20 5 (2005) 1158-1176
104. Ludwig A.K., Glawatz M., Griesinger G., et al. Perioperative and post-operative complications of transvaginal ultrasound-guided oocyte retrieval: prospective study of >1000 oocyte retrievals. Hum Reprod 21 12 (2006) 3235-3240
105. Sauer M.V. Defining the incidence of serious complications experienced by oocyte donors: A review of 1000 cases. Am J Obstet Gynecol (2001) 277-278
106. Azem F., Wolf Y., Botchan A., et al. Massive retroperitoneal bleeding: a complication of transvaginal ultrasonography-guided oocyte retrieval for in vitro fertilization - embryo transfer. Fertil Steril 74 2 (2000) 405-406
107. Coroleu B., Lopez Mourelle F., Hereter L., et al. Case report: ureteral lesion secondary to vaginal ultrasound follicular puncture for oocyte recovery in in-vitro fertilization. Hum Reprod 12 5 (1997) 948-950
108. von Eye Corleta H, Moretto M, D'Avila AM, et al. Case Report: Immediate ureterovaginal fistula secondary to oocyte retrieval - a case report. Fertil Steril 2008; 90(5): 2006.e1-2006.e3.
109. Mongiu AK, Helfand BT, Kielb SJ. Case report: ureterovaginal fistula formation after oocyte retrieval. J Urol 2009; 16(1): 4519-4521.
110. Fiori O., Cornet D., Darai E., et al. Uro-retroperitoneum after ultrasound-guided transvaginal follicle puncture in an oocyte donor: a case report. Hum Reprod 21 11 (2006) 2969-2971
111. Fugita O.E., and Kavoussi L. Case report: laparoscopic ureteral reimplantation for ureteral lesion secondary to transvaginal ultrasonography for oocyte retrieval. J Urol. 58 2 (2001) 281i-281iii
112. El-Shawarby S.A., Margara R.A., Trew G.H., et al. Thrombocythemia and hemoperitoneum after transvaginal oocyte retrieval for in vitro fertilization. Fertil Steril 82 3 (2004) 735-737
113. Moayeri S.E., Coutre S.E., Ramirez E.J., et al. Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval. Am J Obstet Gynecol (2007) e10-e11
114. Battaglia C., Regnani G., Giulini S., et al. J Assist Reprod Genet 18 3 (2001) 178-181
115. Dessole S., Rubattu G., Ambrosini G., et al. Blood loss following noncomplicated transvaginal oocyte retrieval for in vitro fertilization. Fertil Steril 76 1 (2001) 205-206
116. Sharpe K., Karovitch A.J., Claman P., et al. Transvaginal oocyte retrieval for in vitro fertilization complicated by ovarian abcess during pregnancy. Fertil Steril 86 1 (2006) 219.e11-219.e13
117. Kelada E., and Ghani R. Case report: bilateral ovarian abscesses following transvaginal oocyte retrieval for IVF: a case report and review of literature. J Assist Reprod Genet 24 (2007) 143-145
118. Dicker D., Dekel A., Orvieto R., et al. Case report: ovarian abscess after ovum retrieval for in-vitro fertilization. Hum Reprod 13 7 (1998) 1813-1814
119. Akman M.A., Katz E., Damewood M.D., et al. Case report: perforated appendicitis and ectopic pregnancy following in-vitro fertilization. Hum Reprod 10 (1995) 3325-3326